KMT2A and leukemia: CDK6 has been more frequently involved in the progression of hematological malignancy being altered in leukemia, lymphoma, and B-lymphoid malignancies due to chromosomal translocation involving the 7q21 locus and as critical a mediator of Notch signaling in T-cell acute lymphoblastic leukemia (T-ALL) and in MLL-rearranged leukemias, where it blocks myeloid differentiation.328,329 It is also hyperactivated or rearranged in various malignancies, including sarcoma, melanoma, breast cancer, glioma, and medulloblastoma.330,331